This clinical trial is focused on studying treatments for patients with a specific type of breast cancer known as Estrogen Receptor positive (ER+) and Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer. This type of cancer has spread to other parts of the body, such as the liver or lungs, which is referred to as metastatic breast cancer. The study aims to compare two different treatment approaches for this condition. One approach involves using a combination of hormone therapy with a medication called abemaciclib, which is also known by its code name LY2835219. The other approach uses standard chemotherapy treatments, which may include medications like paclitaxel or capecitabine.
The purpose of the study is to determine which treatment is more effective in delaying the progression of the cancer. Participants in the study will be randomly assigned to receive either the hormone therapy with abemaciclib or the chemotherapy. The study will monitor the participants over a period to see how long the cancer can be controlled without worsening. The study will also assess the quality of life of the participants during the treatment period using questionnaires.
Throughout the study, participants will receive regular assessments to track the progress of their treatment. These assessments will include medical tests and evaluations to ensure the safety and effectiveness of the treatments. The study will continue until the estimated end date in 2028, with the goal of providing valuable information on the best treatment options for patients with this type of breast cancer.
France 
